Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Monday, September 23, 2019  Spokane, Washington  Est. May 19, 1883
Partly Cloudy Night 57° Partly Cloudy
News >  Health

FDA approves TB pill that cures more hard-to treat patients

This undated photo provided by the TB Alliance in August 2019 shows the drug pretomanid. (Roksana Bialczak / AP)
This undated photo provided by the TB Alliance in August 2019 shows the drug pretomanid. (Roksana Bialczak / AP)

TRENTON, N.J. – U.S. regulators have approved a new tuberculosis medicine that shortens and improves treatment for the hardest-to-treat cases, a worsening problem in many poor countries.

It’s the first TB drug developed by a nonprofit group, the TB Alliance, which was formed to come up with better treatments.

The Food and Drug Administration approved pretomanid (preh-TOH’-meh-nihd) for use with two other drugs for TB, which attacks the lungs. In testing, the three-pill combo cured about 90% of patients with very drug-resistant TB, usually within six months. It also appears to stop patients spreading the deadly bacterial infection after just a few days’ treatment.

Until now, the best option cured about two-thirds of patients and took 18 to 30 months, according to the TB Alliance.

Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter.

You have been successfully subscribed!
There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com